BRITISH JOURNAL OF ANAESTHESIA INTERMITTENT VS CONTINUOUS EXTRADURAL INFUSION OF BUPIVACAINE DURING LABOUR
Sir,-The absolute significance of the findings of Eddleston and colleagues [1] would have been much clearer if they had compared the two extradural groups with a control group which did not receive extradural bupivacainc. Although this control group would have been self-selected and not subject to randomization, the group could have been matched as closely as possible to the two study groups.
In addition, although the incidence of oxytocin use was recorded in this study, an analysis of the association between oxytocin use and the fetal heart rate abnormalities would have provided additional information. This association is recognized widely, and ascribing heart rate abnormalities to different extradural techniques irrespective of the use of oxytocin may not be valid.
Whilst it is tempting to attribute fetal heart rate abnormalities to uptake of bupivacaine by the fetal myocardium, the evidence for this is far from conclusive. Although Abboud and colleagues [2] also observed fetal heart rate abnormalities after extradural bupivacaine, other factors may have been contributory. In the large majority of cases, abnormalities arc associated with aortocaval compression which is not always diagnosed or recognized [3] . The umbilical vein:maternal vein concentration ratio of bupivacaine is only an index of placental transfer in that it describes the equilibrium concentration ratio of bupivacaine across the placenta at one moment in time. Although Kuhnert and colleagues [4] suggested that low fetal: material ratios were caused by extensive fetal tissue uptake, more recent work in animals by Laishley, Carson and Reynolds [5] does not support this. In our study, in the presence of a constant maternal arterial concentration of bupivacaine, fetal plasma and brain concentrations increased slowly over 120 min and only approached a fetal: maternal ratio of 0.3 at rhat time. Moreover, despite bupivacaine being lipophilic, the fetal brain:fetal blood concentration ratio diminished over this time. This latter rinding indicates that there is not extensive tissue uptake by fetal brain.
The predominant reason for the low fetal: maternal ratio of bupivacaine is the difference in concentration in alpha^acid glycoprotein across the placenta, and the resulting relative difference in the proportion of bupivacaine bound to glycoprotein [6] . Moreover, fetal acidosis, which may be associated with the use of oxytocin, promotes placental transfer of bupivacaine by ion trapping of the basic drug [7] . The study by Reynolds and colleagues [8] confirmed the relatively small fetal plasma concentration of bupivacaine (umbilical samples at delivery) after a large bolus dose of extradural bupivacaine for Caesarean section. If it is hypothesized that bupivacaine causes fetal myocardial toxicity in these small concentrations, then it suggests that the fetal myocardium is much more sensitive than adult myocardium.
Finally, the conclusion of Eddleston and colleagues [1] that there is no advantage in either extradural intermittent bolus or infusion techniques ignores the fact that the infusion technique may be safer. A survey of the Reports on Confidential Enquiries into Maternal Deaths between 1970 and 1987 [9] reveals that four of the 10 deaths directly associated with extradural analgesia were caused by total spinal anaesthesia and extradural bolus doses of bupivacaine. So far, there are no descriptions in these reports [9] of any death associated with an extradural infusion.
R. S. LAISHLEY

Eating Hospital London
Sir,-Thank you for the opportunity of replying to Dr Laishley's detailed letter. Our study was an attempt to examine, in particular, the potential effects on the fetus of extradural analgesia with bupivacaine. Exhaustive studies comparing intermittent and continuous infusion extradural analgesia with bupivacaine failed to demonstrate any maternal advantage associated with either regimen [1, 2] . To date, no attention has been paid to the effect of the two regimens on the fetus, in particular fetal heart rate pattern.
In our study, we documented 71 dcceleratory episodes in the intermittent group and 69 in the infusion group. We found no difference between groups in the incidence of deceleration occurring within 30 min of an extradural top-up, but we did detect a discrepancy in its severity and duration. In the intermittent group, the majority of decelerations (73.8 %) were recorded as transient, whereas in the infusion group 61.1 % of episodes lasted in excess of 10 min. Indeed, there are several other potential causes for fetal heart rate decelerations, including aortocaval compression producing hypotension, the use of oxytocics and fetal acidosis, all of which are referred to in Dr Laishley's letter. I can restate that none of the deceleratory episodes referred to in our paper occurred in the presence of maternal upper limb hypotension. Obviously, this does not exclude the presence of concealed aortocaval compression. In addition, there was no difference in die mean dose of oxytocic required by each treatment group or in the acid-base status of the two groups at delivery.
Finally, we accept Dr Laishley's comments concerning a control group. Such a group almost universally would have received another form of analgesia, most probably parenteral pethidine. We do not feel that this could be described as a control group.
In conclusion, we wish to restate that there is no advantage to either mother or fetus in using an extradural infusion of 0.125 % bupivacaine compared with intermittent injections of 0.25% bupivacaine. We accept, however, that the infusion technique should, in theory, be less likely to produce total spinal anaesthesia in the case of a misplaced extradural catheter. 
DOES ETOMIDATE CAUSE HAEMOLYSIS?
Sir,-I read with interest the article "Does etomidate cause haemolysis ? " by Ncbauer and colleagues [ 1] , as it reminded me of an unreported finding after etomidate use in domestic cats. We conducted research several years ago at the Veterinary Teaching Hospital at the University of Illinois to determine the anaesthetic effects and pharmacokinetics of etomidate in domestic cats [2, 3] . We used Amidate i.v. (Abbott Laboratories) in a dose of 3 mg kg"
